Rock Springs Capital Management LP - Q1 2023 holdings

Add to watchlist

$4.19 Billion is the total value of Rock Springs Capital Management LP's 121 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 8.5% .

All
New
Buy
Sell
Exit
Unchanged
 Value Shares↓ Weighting
AGL BuyAGILON HEALTH INC$187,209,375
+47.3%
7,882,500
+0.1%
4.47%
+46.1%
PODD BuyINSULET CORP$171,201,780
+10.9%
536,750
+2.4%
4.08%
+10.0%
NBIX BuyNEUROCRINE BIOSCIENCES INC$122,486,322
-8.6%
1,210,100
+7.8%
2.92%
-9.4%
BPMC BuyBLUEPRINT MEDICINES CORP$91,466,830
+10.4%
2,033,048
+7.5%
2.18%
+9.4%
KRTX BuyKARUNA THERAPEUTICS INC$89,644,244
+10.3%
493,527
+19.3%
2.14%
+9.4%
HZNP BuyHORIZON THERAPEUTICS PUB L$80,774,514
-4.0%
740,100
+0.1%
1.93%
-4.9%
WST BuyWEST PHARMACEUTICAL SVSC INC$69,986,940
+60.3%
202,000
+8.9%
1.67%
+59.0%
ALNY BuyALNYLAM PHARMACEUTICALS INC$69,110,400
-12.5%
345,000
+3.8%
1.65%
-13.3%
EXAS BuyEXACT SCIENCES CORP$63,843,115
+45.3%
941,500
+6.1%
1.52%
+44.1%
ACHC BuyACADIA HEALTHCARE COMPANY IN$62,197,713
-10.6%
860,868
+1.8%
1.48%
-11.4%
CERE BuyCEREVEL THERAPEUTICS HLDNG I$61,314,411
-22.4%
2,513,916
+0.3%
1.46%
-23.1%
SRPT BuySAREPTA THERAPEUTICS INC$60,989,775
+8.0%
442,500
+1.5%
1.46%
+7.1%
AKRO BuyAKERO THERAPEUTICS INC$55,639,758
-27.5%
1,454,254
+3.8%
1.33%
-28.1%
RARE BuyULTRAGENYX PHARMACEUTICAL IN$53,589,680
-10.4%
1,336,401
+3.6%
1.28%
-11.1%
FRPT BuyFRESHPET INC$43,850,875
+26.5%
662,500
+0.8%
1.05%
+25.4%
BuyAMYLYX PHARMACEUTICALS INC$42,625,621
-6.2%
1,452,816
+18.1%
1.02%
-7.0%
XENE BuyXENON PHARMACEUTICALS INC$42,160,692
-9.1%
1,178,002
+0.2%
1.01%
-9.8%
BMEA BuyBIOMEA FUSION INC$40,226,575
+552.9%
1,297,213
+77.5%
0.96%
+548.6%
MRTX BuyMIRATI THERAPEUTICS INC$39,606,404
+8.6%
1,065,261
+32.3%
0.94%
+7.6%
OLK BuyOLINK HLDG ABsponsored ads$37,174,500
+1.4%
1,650,000
+14.2%
0.89%
+0.6%
ACCD BuyACCOLADE INC$36,597,100
+142.4%
2,545,000
+31.3%
0.87%
+140.5%
KYMR BuyKYMERA THERAPEUTICS INC$36,396,870
+18.8%
1,228,379
+0.0%
0.87%
+17.8%
ACRS BuyACLARIS THERAPEUTICS INC$32,051,358
-48.6%
3,961,849
+0.0%
0.76%
-49.0%
ABCM BuyABCAM PLCads$30,184,050
-11.0%
2,242,500
+2.9%
0.72%
-11.8%
TVTX BuyTRAVERE THERAPEUTICS INC$28,711,859
+43.5%
1,276,650
+34.2%
0.68%
+42.1%
LEGN BuyLEGEND BIOTECH CORPsponsored ads$22,097,538
-1.7%
458,265
+1.7%
0.53%
-2.6%
LFST BuyLIFESTANCE HEALTH GROUP INC$21,547,000
+61.5%
2,900,000
+7.4%
0.51%
+60.1%
BCRX BuyBIOCRYST PHARMACEUTICALS INC$19,466,269
-10.3%
2,334,085
+23.4%
0.46%
-11.1%
BRKS BuyAZENTA INC$19,240,144
-6.0%
431,200
+22.7%
0.46%
-6.7%
INZY BuyINOZYME PHARMA INC$18,421,377
+468.5%
3,214,900
+4.2%
0.44%
+464.1%
NewMINERALYS THERAPEUTICS INC$18,282,925–1,167,492
+100.0%
0.44%–
CMPX BuyCOMPASS THERAPEUTICS INC$18,030,087
-32.8%
5,513,788
+3.4%
0.43%
-33.3%
IMTX BuyIMMATICS N.V$17,346,069
-12.5%
2,513,923
+10.5%
0.41%
-13.2%
CYTK BuyCYTOKINETICS INC$15,751,044
-22.4%
447,600
+1.0%
0.38%
-23.0%
RVMD NewREVOLUTION MEDICINES INC$15,220,742–702,712
+100.0%
0.36%–
BuyWARBY PARKER INC$13,767,000
-16.3%
1,300,000
+6.6%
0.33%
-17.2%
PLRX NewPLIANT THERAPEUTICS INC$13,066,479–491,221
+100.0%
0.31%–
EDAP BuyEDAP TMS S Asponsored adr$11,402,100
+17.5%
1,030,000
+13.2%
0.27%
+16.7%
BuyBIOHAVEN LTD$9,365,610
+0.9%
685,623
+2.5%
0.22%0.0%
SPRB BuySPRUCE BIOSCIENCES INC$6,029,156
+238.6%
2,728,125
+68.1%
0.14%
+234.9%
BuyICOSAVAX INC$5,014,158
-19.1%
864,510
+10.7%
0.12%
-19.5%
BuyXILIO THERAPEUTICS INC$4,567,206
+24.6%
1,440,759
+5.7%
0.11%
+23.9%
NVTA BuyINVITAE CORP$4,375,924
-24.0%
3,241,425
+4.6%
0.10%
-25.2%
NVAX BuyNOVAVAX INC$3,710,322
-32.2%
535,400
+0.5%
0.09%
-32.6%
FATE BuyFATE THERAPEUTICS INC$3,489,626
+214.4%
612,215
+456.6%
0.08%
+207.4%
ADAP BuyADAPTIMMUNE THERAPEUTICS PLCsponds adr$3,038,751
-22.2%
2,787,845
+4.2%
0.07%
-22.3%
ETNB New89BIO INCcall$2,505,335–164,500
+100.0%
0.06%–
FULC BuyFULCRUM THERAPEUTICS INC$2,073,868
-25.9%
727,673
+89.2%
0.05%
-26.9%
LPTX BuyLEAP THERAPEUTICS INC$1,582,763
-3.9%
4,655,186
+27.2%
0.04%
-5.0%
GOSS BuyGOSSAMER BIO INC$1,386,345
+69.9%
1,100,274
+192.6%
0.03%
+65.0%
APLT BuyAPPLIED THERAPEUTICS INC$633,300
+39.7%
780,791
+30.9%
0.02%
+36.4%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
INTUITIVE SURGICAL INC40Q3 20233.4%
NEUROCRINE BIOSCIENCES INC39Q3 20234.8%
PACIRA PHARMACEUTICALS INC39Q3 20232.6%
ULTRAGENYX PHARMACEUTICAL IN39Q3 20231.9%
ACADIA HEALTHCARE COMPANY IN38Q3 20234.4%
ASCENDIS PHARMA A/S35Q3 20231.3%
INVITAE CORP35Q3 20231.8%
BIOMARIN PHARMACEUTICAL INC35Q3 20231.3%
MACROGENICS INC35Q3 20230.5%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.1%

View Rock Springs Capital Management LP's complete holdings history.

Latest significant ownerships (13-D/G)
Rock Springs Capital Management LP Q1 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Aeglea BioTherapeutics, Inc.February 14, 20233,413,9065.6%
Compass Therapeutics, Inc.February 14, 20235,333,1884.2%
Mirum Pharmaceuticals, Inc.February 14, 20231,795,7334.9%
PhaseBio Pharmaceuticals IncSold outFebruary 14, 202300.0%
Sierra Oncology, Inc.Sold outFebruary 14, 202300.0%
ARDELYX, INC.Sold outFebruary 15, 202200.0%
CHIASMA, INCSold outFebruary 15, 202200.0%
FIVE PRIME THERAPEUTICS, INC.Sold outFebruary 15, 202200.0%
F-star Therapeutics, Inc.February 15, 2022751,8893.6%
Protara Therapeutics, Inc.Sold outFebruary 15, 202200.0%

View Rock Springs Capital Management LP's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G2024-05-01
SC 13G/A2024-04-05
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Rock Springs Capital Management LP's complete filings history.

All filings

View complete filings history.

Compare quarters

Export Rock Springs Capital Management LP's holdings

CSVXLS